Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Yong-Lian Zhu"'
Autor:
Z. Ping Lin, Nour N. Al Zouabi, Mark L. Xu, Nicole E. Bowen, Terence L. Wu, Ethan S. Lavi, Pamela H. Huang, Yong-Lian Zhu, Baek Kim, Elena S. Ratner
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-21 (2021)
Abstract Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR
Externí odkaz:
https://doaj.org/article/7c21bcf75bea4e2ebab41ede567eddbb
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Ovarian, uterine/endometrial, and cervical cancers are major gynecologic malignancies estimated to cause nearly 30,000 deaths in 2018 in US. Defective cell cycle regulation is the hallmark of cancers underpinning the development and progression of th
Externí odkaz:
https://doaj.org/article/a1734289e7e34dff8ba0db975bd19306
Autor:
Z Ping Lin, Yong-Lian Zhu, Ying-Chun Lo, Jake Moscarelli, Amy Xiong, Yasmin Korayem, Pamela H Huang, Smith Giri, Patricia LoRusso, Elena S Ratner
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0207399 (2018)
PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging. The objective of th
Externí odkaz:
https://doaj.org/article/8eb6c3a956554389b6add7b11b7c16be
Autor:
Pamela H Huang, Nicole E. Bowen, Baek Kim, Nour N Al Zouabi, Mark L Xu, Terence L. Wu, Yong-Lian Zhu, Elena Ratner, Z. Ping Lin, Ethan S Lavi
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-21 (2021)
Scientific Reports
Scientific Reports
Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR repair in
Autor:
Jake Moscarelli, Z. Ping Lin, Yong-Lian Zhu, Ying-Chun Lo, Smith Giri, Amy Xiong, Elena Ratner, Pamela H Huang, Yasmin Korayem, Patricia LoRusso
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 11, p e0207399 (2018)
PLoS ONE, Vol 13, Iss 11, p e0207399 (2018)
PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging. The objective of th
Autor:
Peter Boyle, H Sayward, Tongzhang Zheng, Chu Chen, Zhibin Hu, Yaqun Zhang, Ni Li, Hongbing Shen, Theodore R. Holford, Yong-Lian Zhu, Min Dai, Stephen M. Schwartz, S Honig, Bryan A. Bassig, P Morey, Russ Hauser, Pablo Gomery
Publikováno v:
British Journal of Cancer. 112:1247-1250
Muscle-building supplement use and increased risk of testicular germ cell cancer in men from Connecticut and Massachusetts
Autor:
Alan C. Sartorelli, Raymond P. Baumann, Rui Zhu, Philip G. Penketh, Rick A. Finch, Yong Lian Zhu, Krishnamurthy Shyam
Publikováno v:
Journal of Medicinal Chemistry. 58:3639-3671
1,2-Bis(sulfonyl)-1-alkylhydrazines (BSHs) were conceived as more specific DNA guanine O-6 methylating and chloroethylating agents lacking many of the undesirable toxicophores contained in antitumor nitrosoureas. O(6)-Alkylguanine-DNA alkyltransferas
Autor:
Rui Zhu, Yong-Lian Zhu, Philip G. Penketh, Pamela H Huang, Yashang Lee, Kimiko Ishiguro, Alan C. Sartorelli, Elena Ratner, Margaret Whicker, Z. Ping Lin, Julie Berenblum
Publikováno v:
British Journal of Cancer
Background: Platinum resistance may be attributable to inherent or acquired proficiency in homologous recombination repair (HRR) in epithelial ovarian cancer (EOC). The objective of this study was to evaluate the efficacy of the small molecule inhibi
Autor:
Krishnamurthy Shyam, Alan C. Sartorelli, Kimiko Ishiguro, Raymond P. Baumann, Yong-Lian Zhu, Philip G. Penketh
Publikováno v:
Biochemical Pharmacology. 80:1317-1325
O 6 -Alkylguanine-DNA alkyltransferase (AGT) mediates tumor resistance to alkylating agents that generate guanine O 6 -chloroethyl (Onrigin™ and carmustine) and O 6 -methyl (temozolomide) lesions; however, the relative efficiency of AGT protection
Publikováno v:
Journal of Clinical Oncology. 36:e17551-e17551
e17551Background: PARP inhibitors target BRCA-mutated or homologous recombination (HR) repair-defective epithelial ovarian cancer (EOC). However, primary and recurrent EOC with proficient HR repair...